These findings suggest that the SGLT2 inhibitors treatment offers an optimal strategy for improving NT-proBNP and health status (assessed by Kansas City Cardiomyopathy Questionnaire and 6-minute walk distance) in CHF patients with or without T2DM. Here, SLC5A2 is linked to type 2 diabetes mellitus.